Fig. 2.

Sorafenib impairs cell viability and proliferation in MPM primary cultures enriched in TICs. a Time and dose-dependent effects of sorafenib on cell survival assessed by MTT assays, in MM1, MM3, and MM4 cells treated with increasing amounts of sorafenib for 24, 48, and 72 h. Each point represents quadruplicate replicates from at least three independent experiments. Data presented as the percentage of viable cells compared with control (vehicle-treated) cells, expressed as mean ± SEM. b Sorafenib impairs DNA synthesis in MPM TICs. Detection of proliferating cells was evaluated by BrdU DNA incorporation in MM1, MM3, and MM4 cells cultured for 48 h in the presence and the absence of sorafenib (administered at the respective IC₅₀ values). Data expressed as mean % ± SD. *p <0.05, **p <0.01 vs respective controls. CTR control, BrdU 5-bromo-2′-deoxyuridine